Top Markets
Coin of the day
PCL, Inc. PCL, Inc.

PCL, Inc.

241820
주식 순위 #31786
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic... PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
주가
$0.21291741
마지막 동기화: 2025-04-18
시가총액
$12.07M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
KR
거래 PCL, Inc. (241820)

카테고리

PCL, Inc. (241820)의 매출
Sep 2025 기준 매출 TTM: $3.55M
PCL, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $3.55M입니다. 2023년에 회사는 $6.51M의 수익을 올렸으며 이는 2022년의 $29.49M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
PCL, Inc.의 수익 기록 (2015 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $3.55M 318.67%
2024 $847.63K -86.98%
2023 $6.51M -77.92%
2022 $29.49M -24.02%
2021 $38.82M -21.50%
2020 $49.45M 159,346.74%
2019 $31.01K -73.14%
2018 $115.44K -75.69%
2017 $474.92K -2.74%
2016 $488.29K 136.13%
2015 $206.79K 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$46.59B 1,312,601.74%
US
$25.84B 727,951.41%
US
$35.48B 999,790.71%
IE
$21.00B 591,538.63%
US
$6.51B 183,407.73%
US